Adapting, Partnering, and Innovating: Insights from CPhI Frankfurt
How CDMOs are navigating uncertainty, forging partnerships, and embracing flexibility.
Recipharm
Meribel Pharma Solutions Launches
A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions, has launched today with an extensive integrated network across Europe.
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Recipharm Bolsters Blow-Fill-Seal Capabilities in France
Swedish multinational CDMO Recipharm has bolstered its sterile filling capabilities at its facility in Kaysersberg, France, by installing Lab+ continuous automated technology.
Recipharm Buys US CDMO Arranta Bio
Sweden’s Recipharm is acquiring US CDMO Arranta Bio for an undisclosed sum. The deal, expected to close around the end of March, establishes a strong US presence for Recipharm and provides a further platform for building capabilities in new biologics molecules.
Recipharm Divests Sites in France and the UK
Over the course of January, Swedish CDMO Recipharm has sold two of its manufacturing sites to two different buyers in two different countries. One of the divested sites is at Fontaine-lès-Dijon, France, and the other in Newcastle, UK.
Recipharm Expands Israel Capacity
Swedish CDMO Recipharm is investing in a capacity expansion at its facility located south of Tel Aviv in Israel, in order to support growing demand for cGMP clinical supply of APIs and intermediates.
Expert Interview: Mark Quick, Recipharm
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
